|
Market Closed -
Other stock markets
|
After hours 21:32:00 | |||
| 17.58 USD | -0.17% |
|
17.78 | +1.11% |
| 04-15 | Kimberly-Clark Discloses Organizational Structure After Planned Kenvue Acquisition | MT |
| 04-15 | Kimberly-Clark retains Urdaneta as CFO of combined company after $40-billion Kenvue deal | RE |
Business description: Kenvue Inc.
- self care products (42,3%): for the treatment of coughs, colds, allergies, pain, indigestion, constipation, etc. (brands Zyrtec, Benadryl, Zarbee's, Frenadol, Codral, Reactine, Tylenol, Motrin, Calpol, Nicorette, Imodium, Pepcid, Microlax, Daktarin, etc.);
- personal care products (30.3%): primarily oral care, baby care, women's health and wound care products (Listerine, Desitin, Carefree, Stayfree, Band-Aid, Neosporin brands, etc.);
- beauty and skin care products (27.4%): hair care products, sun protection products, face and body care products, etc. (Neutrogena, Aveeno, Clean&Clear, Lubriderm, Johnsons, Neostrata, OGX, Rogaine brands, etc.).
Product marketing is assured through direct sales, distributors and the Internet.
Net sales are distributed geographically as follows: North America (49%), Europe-Middle East-Africa (23%), Asia-Pacific (19.3%) and Latin America (8.7%).
Number of employees: 21,890
Sales by Activity: Kenvue Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Self Care | 5.64B | 6.03B | 6.45B | 6.53B | 6.38B |
Essential Health | 4.87B | 4.57B | 4.62B | 4.69B | 4.63B |
Skin Health and Beauty | 4.54B | 4.35B | 4.38B | 4.24B | 4.11B |
Geographical breakdown of sales: Kenvue Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
North America | 7.28B | 7.42B | 7.61B | 7.58B | 7.26B |
Europe, Middle East, and Africa | 3.44B | 3.19B | 3.39B | 3.56B | 3.72B |
Asia-Pacific | 3.28B | 3.15B | 3.11B | 2.97B | 2.78B |
Latin America | 1.06B | 1.2B | 1.34B | 1.34B | 1.37B |
Executive Committee: Kenvue Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Kirk Perry
CEO | Chief Executive Officer | 59 | 13/07/2025 |
Amit Banati
DFI | Director of Finance/CFO | 57 | 11/05/2025 |
| Chief Tech/Sci/R&D Officer | 57 | - | |
Caroline Tillett
CTO | Chief Tech/Sci/R&D Officer | 54 | 30/04/2023 |
Bernardo Tavares
CTO | Chief Tech/Sci/R&D Officer | 58 | 30/04/2023 |
Composition of the Board of Directors: Kenvue Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Larry Merlo
CHM | Chairman | 70 | 30/04/2023 |
Vasant M. Prabhu
BRD | Director/Board Member | 66 | 03/05/2023 |
Richard Allison
BRD | Director/Board Member | 59 | 07/05/2023 |
| Director/Board Member | 56 | 07/05/2023 | |
Melanie Healey
BRD | Director/Board Member | 64 | 07/05/2023 |
Betsy Holden
BRD | Director/Board Member | 70 | 07/05/2023 |
Michael Sneed
BRD | Director/Board Member | 67 | 07/05/2023 |
Kathleen Pawlus
BRD | Director/Board Member | 66 | 14/08/2024 |
Kirk Perry
BRD | Director/Board Member | 59 | 30/11/2024 |
Sarah Hofstetter
BRD | Director/Board Member | 52 | 04/03/2025 |
Company details: Kenvue Inc.
Group companies: Kenvue Inc.
| Name | Category and Sector |
|---|---|
McNeil AB
 McNeil AB Pharmaceuticals: MajorHealth Technology Develops and manufactures medicines |
Pharmaceuticals: Major
|
McNeil AB
McNeil AB Pharmaceuticals: MajorHealth Technology Develops and manufactures medicines |
Pharmaceuticals: Major
|
Other Personal Products
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.17% | +1.85% | -21.06% | - | 33.81B | |
| -1.66% | +0.63% | -12.83% | -4.22% | 341B | |
| -0.70% | -1.02% | -21.04% | -12.60% | 127B | |
| -2.05% | -0.54% | -11.80% | +9.39% | 68.85B | |
| -0.42% | +3.54% | -6.04% | -11.85% | 62.59B | |
| +2.17% | +4.43% | +43.13% | -69.88% | 27.56B | |
| -1.48% | +2.76% | -35.06% | -37.24% | 20.26B | |
| -1.50% | +0.16% | -12.82% | -19.05% | 18.85B | |
| -0.41% | +2.48% | -10.85% | +14.15% | 12.27B | |
| -1.19% | +5.47% | +475.69% | - | 10.75B | |
| Average | -0.73% | +2.92% | +38.73% | -16.41% | 72.37B | |
| Weighted average by Cap. | -1.11% | +1.61% | -5.17% | -8.84% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- KVUE Stock
- Company Kenvue Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition